<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822991</url>
  </required_header>
  <id_info>
    <org_study_id>JLOG08001</org_study_id>
    <secondary_id>UMIN000001612</secondary_id>
    <nct_id>NCT00822991</nct_id>
  </id_info>
  <brief_title>Sonazoid Enhanced Liver Cancer Trial for Early Detection</brief_title>
  <official_title>Sonazoid Enhanced Liver Cancer Trial for Early Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Liver Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Liver Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using
      Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound
      (B-mode US) for hepatitis virus related cirrhosis, who are defined as super high-risk
      patients for hepatocarcinogenesis,Furthermore, to analyze whether early detection of HCC by
      CE-US has a survival benefit than that by B-mode US.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of HCC which is detected first</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to detection of HCC</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of prognosis of patients who are diagnosed in this study</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group of CE-US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group of B-mode US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>screening by conventional B-mode US every 3-5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CE-US (Sonazoidâ„¢)</intervention_name>
    <description>screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months</description>
    <arm_group_label>Group of CE-US</arm_group_label>
    <other_name>Sonazoid Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B-mode US</intervention_name>
    <description>screening by conventional B-mode US every 3-5 months</description>
    <arm_group_label>Group of B-mode US</arm_group_label>
    <other_name>B-mode Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 20

          2. HBV or HCV related liver cirrhosis

          3. No history of HCC

          4. Diagnosed as liver cirrhosis histologically or clinically Histologically confirmed by
             liver biopsy Confirmed by formula of diagnosing cirrhosis Radiological finding Finding
             of portal hypertension Platelet&lt;130,000

          5. Inpatient or outpatient

          6. Patients who signed a written informed consent form

        Exclusion Criteria:

          1. History of hypersensitivity to egg yolk

          2. Pregnant or lactating women and women who may be pregnant

          3. Severe liver dysfunction(AST, ALT,or BIL level &gt;10ULN

          4. Associated with HCC

          5. Patients receiving interferon

          6. Age under 20

          7. Judged by investigator not to be appropriate for inclusion in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masatoshi Kudo, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Japan Liver Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masatoshi Kudo, professor</last_name>
    <phone>+81-72-366-0221</phone>
    <phone_ext>3149</phone_ext>
    <email>m-kudo@med.kindai.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kazuomi Ueshima, lecturer</last_name>
    <phone>+81-72-366-0221</phone>
    <phone_ext>3525</phone_ext>
    <email>kaz-ues@med.kindai.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kinki University School of Medicine, Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Osaka-Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masatoshi Kudo, professor</last_name>
      <phone>+81-72-366-0221</phone>
      <phone_ext>3149</phone_ext>
      <email>m-kudo@med.kindai.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kazuomi Ueshima, lecturer</last_name>
      <phone>+81-72-366-0221</phone>
      <phone_ext>3525</phone_ext>
      <email>kaz-ues@med.kindai.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>December 29, 2010</last_update_submitted>
  <last_update_submitted_qc>December 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Japan Liver Oncology Group</name_title>
    <organization>Kinki University School of Medicine, Gastroenterology and Hepatology</organization>
  </responsible_party>
  <keyword>Sonazoid</keyword>
  <keyword>Early detection</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

